Weekly semaglutide injections associated with significant weight loss in adults
In short: A clinical trial of 1,961 adults with overweight or obesity found that once-weekly semaglutide injections, combined with lifestyle changes, led to substantial weight reduction. Over 69% of participants in the semaglutide group lost at least 10% of their body weight after 68 weeks, compared to only 12% in the placebo group.
The study demonstrated that semaglutide can lead to sustained, clinically relevant weight reduction in adults without diabetes.
Researchers used a double-blind, randomized trial design, but the study noted that gastrointestinal side effects like nausea and diarrhea caused some participants to discontinue treatment.
Why it matters: Semaglutide shows potential for significant, sustained weight reduction when used alongside lifestyle interventions.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Research: Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine.
To cite this card, link to https://intellectplus.co.uk/app/health-research-weekly-semaglutide-injections-associated-with-significant-we.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Medicines · More in Health · Latest · A–Z · All topics
